Raghu Nadhanan R, Abimosleh SM, Su YW, Scherer MA, Howarth GS, Xian CJ. Dietary emu oil supplementation suppresses 5-fluorouracil chemotherapy-induced inflammation, osteoclast formation, and bone loss. Am J Physiol Endocrinol Metab 302: E1440 -E1449, 2012. First published March 20, 2012; doi:10.1152/ajpendo.00587.2011Cancer chemotherapy can cause osteopenia or osteoporosis, and yet the underlying mechanisms remain unclear, and currently, no preventative treatments are available. This study investigated damaging effects of 5-fluorouracil (5-FU) on histological, cellular, and molecular changes in the tibial metaphysis and potential protective benefits of emu oil (EO), which is known to possess a potent anti-inflammatory property. Female dark agouti rats were gavaged orally with EO or water (1 ml·day Ϫ1 ·rat Ϫ1 ) for 1 wk before a single ip injection of 5-FU (150 mg/kg) or saline (Sal) was given. The treatment groups were H2O ϩ Sal, H2O ϩ 5-FU, EO ϩ 5-FU, and EO ϩ Sal. Oral gavage was given throughout the whole period up to 1 day before euthanasia (days 3, 4, and 5 post-5-FU). Histological analysis showed that H2O ϩ 5-FU significantly reduced heights of primary spongiosa on days 3 and 5 and trabecular bone volume of secondary spongiosa on days 3 and 4. It reduced density of osteoblasts slightly and caused an increase in the density of osteoclasts on trabecular bone surface on day 4. EO supplementation prevented reduction of osteoblasts and induction of osteoclasts and bone loss caused by 5-FU. Gene expression studies confirmed an inhibitory effect of EO on osteoclasts since it suppressed 5-FU-induced expression of proinflammatory and osteoclastogenic cytokine TNF␣, osteoclast marker receptor activator of nuclear factor-B, and osteoclast-associated receptor. Therefore, this study demonstrated that EO can counter 5-FU chemotherapy-induced inflammation in bone, preserve osteoblasts, suppress osteoclast formation, and potentially be useful in preventing 5-FU chemotherapy-induced bone loss.
treat adult patients suffering from colorectal and breast cancer, whereas in children 5-FU is used to treat childhood solid tumours (27, 36) . 5-FU inhibits thymidylate synthase, an enzyme required to synthesize thymine nucleotide, which is important for synthesis of DNA and RNA (27) . In an acute 5-FU chemotherapy model in rats, reduced primary spongiosa height and decreased bone volume in the secondary spongiosa of the metaphysis were observed, suggesting that 5-FU can significantly affect bone growth (48) .
Chemotherapeutic agents such as 5-FU, MTX, cyclophosphamide, and etoposide have been shown to cause severe osteopenia by suppressing bone-forming cells (osteoblasts) and promoting recruitment of bone-degrading cells (osteoclasts) (49 -51) . However, the underlying molecular mechanisms of chemotherapy-induced bone defects still remain largely unknown. Osteoclasts are differentiated from monocyte/macrophage precursor cells under the influence of TNF␣-related cytokine, namely receptor activator of nuclear factor-B ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) (6) . Osteoprotegerin (OPG), being the decoy receptor produced by osteoblasts, competitively inhibits the binding of RANKL to RANK and thus suppresses the production of osteoclasts (30) . However, a noncanonical pathway of osteoclastogenesis also exists, in which proinflammatory cytokines such as TNF␣ and interleukin-6 (IL-6) play a role in osteoclast formation and bone loss (15, 21) . These proinflammatory cytokines have been shown to be upregulated and responsible for causing tissue inflammation and to stimulate formation and activity of osteoclasts through the RANKL/RANK-dependent or -independent pathway (20, 37, 40) .
Currently, there are no safe and cost-effective treatments against chemotherapy-induced bone loss. The available antiresorptive therapies using bisphosphonates are known to reduce resorption and increase bone mass and thus have some efficacy in preventing/reducing osteoporosis (17) . A review (34) has indicated that there have been attempts at using bisphosphonates to ameliorate the possible side effects of cancer-induced or treatment-induced bone loss. However, one study has shown that there were no significant changes in terms of bone loss between the treatment groups receiving oral risedronate or placebo, which has called into question the correct dosing of bisphosphonates (16) . The review (34) has also mentioned that bisphosphonates inhibit the formation of new bone as well as bone resorption and that the increase in bone density seen in some studies involving the use of bisphosphonates might be due to the increased mineralization of the old bone and inhibition of the new soft bone. However, high costs involved in their administration and occasional toxicities and side effects, including brittle bones due to suppressed bone turnover, have limited their widespread usage, and the cost-effectiveness of their usage or long-term use has been questioned (9, 33) . Considering cost-effectiveness, safety, and ease of administration, one attractive approach would be to use a nutraceutical as a dietary supplement to aid skeletal health. Emu (Dromaius novaehollandiae), traditionally native to Australia, are now farmed around the world for their meat, leather, and, most recently, oil (47) . Emu oil (EO) is extracted from both the subcutaneous and retroperitoneal fat of the bird by first rendering the macerated tissue and then passing the liquefied fat through a series of filters to obtain purified oil (4) . EO is composed predominately of fatty acids, with a lipid content of 98.8% for the subcutaneous adipose tissue and 98% for the retroperitoneal adipose tissue. EO is a natural source of 18:1 (n-9) fatty acid (oleic acid), which constitutes ϳ43-46% of the fatty acid composition, with 18:3 (n-3) linolenic acid (9.6%), palmitic acid (23.5%), and 18:2 (n-6) linoleic acid (0.6%) (53) . The remaining 1-2% is yet to be identified; however, natural antioxidants such as carotenoids and flavones are present in the EO (24) . EO has been used as an anti-inflammatory agent by Australian aboriginals to treat arthritis and joint pains for hundreds of years (43) . Recent studies have focused on the effects of EO on arthritis and dermal inflammation in animal models (47, 53) . Topical application of EO to animals has been shown to reduce the levels of TNF␣ and other proinflammatory cytokines in a model of adjuvant-induced inflammation (53) . Previous studies comparing different oils showed that EO was most potent in reducing adjuvant-induced dermal inflammation (53) . More recently, dietary EO supplementation has been shown to be efficacious at reducing intestinal tissue damage and inflammation caused by 5-FU chemotherapy (1, 24) . However, whether EO can protect bone from inflammatory bone loss during chemotherapy remains unknown. In the current study, an acute 5-FU chemotherapy model was used to examine whether a local inflammatory condition in bone is associated with bone loss and to investigate whether the potent anti-inflammatory nutraceutical EO can potentially prevent bone loss caused by chemotherapy.
MATERIALS AND METHODS
Animal trials with 5-FU and EO. EO was prepared by utilizing specific methodologies developed for Technology Investment by Emu Tracks Pty (Marleston, Adelaide, South Australia, Australia). Briefly, these processes involved rendering and filtration of emu adipose tissue, with appropriate considerations for delivery of quality assurance and product consistency (24) . The fatty acid composition of EO used in this study is provided (Table 1) , and this emu oil contained the energy content of 38 kJ/g oil. Young adult female dark agouti rats (6 wk old) were used in this study because they can be induced to bear tumours, which would be useful for further studies with a tumourbearing model. Non-tumour-bearing female agouti rats (110 -150 g body wt) with ad libitum access to water and an 18% casein-based diet were used in this study (Table 2) .
Animals were pretreated via oral gavage of water or EO for 1 wk prior to the induction of a chemotherapy regimen. At the conclusion of this 1-wk pretreatment phase, animals were divided into treatment groups for injection with either 5-FU or a saline control. The rats were subjected to one single intraperitoneal injection of saline (as control) or 5-FU (Mayne Pharma, Mulgrave, Victoria, Australia) at 150 mg/kg body wt (48, 52) . This dose is known to be well tolerated and corresponds to a human dosage of 457 mg/m 2 , which is within the therapeutic range (370 -500 mg/m 2 for 5 days), as described (5). Oral gavage treatment was continued up to the day of euthanasia. Thus, in total, four treatment groups were investigated: H2O ϩ Sal (saline), H2O ϩ 5-FU, EO ϩ 5-FU, and EO ϩ Sal. Three time points were evaluated for each group (days 3, 4, and 5 post-saline/5-FU), whereby the rats were humanely euthanized by CO2 overdose for specimen collection for observing time course damage and recovery in bone, as described (52) . Eight animals per group per time point were evaluated; thus a total of 32 rats were used in this study. Days 3, 4, and 5 postchemotherapy regimen induction were selected for study because in our previous study using the same model of 5-FU chemotherapy but with a different strain and sex of rats (48), we observed that, although there were a significant induction of osteoblast apoptosis and a suppression of osteoblast proliferation on days 1 and 2, there were no obvious structural changes of metaphyseal trabecular bone on these two early time points. However, we had observed a significant reduction in heights of metaphyseal primary spongiosa on days 3 and 5 in this previous study. Therefore, in the current study, we have focused our analysis on days 3, 4, and 5.
Water was used as the control based on previous studies (1, 24) involving the use of 5-FU and EO for the same duration of time, in which no significant differences in the body weight gain of rats were found between the water-treated group and the EO-treated group. In addition, since to date there is no information available on the relationship between EO bioactivity, metabolism, and body weight, a set amount (unadjusted by body weight) of emu oil (1.0 ml/day, a Specimen collection. Both hind limbs of each rat were dissected. The proximal left tibia was collected, fixed in 10% formalin for 24 h, decalcified in Immunocal (Decal, Tallman, NY) at 4°C, processed, and embedded in paraffin wax. Paraffin sections 4 m thick were cut and mounted on positively charged SuperFrost Plus glass slides for histological analysis. The right proximal tibia was dissected free of soft tissues before fresh growth plate cartilage and 0.4 mm of metaphyseal bone were obtained using a clean blade. The fresh tissues were then snap-frozen in liquid nitrogen before being stored at Ϫ80°C until RNA isolation.
Remaining femur, tibia, and humerus were collected and used to obtain bone marrow samples by removing both ends of bones and placing in an eppendorf tube before being centrifuged at 900 g in a microfuge at 4°C for 5 min. A previous study has reported that the bone marrow stromal cells obtained from the femur and tibia of rats respond the same way to treatment with MTX (another commonly used antimetabolite) (14) . Therefore, to obtain a large enough number of cells to perform the cell culture assays needed, more than one marrow cavity was used to obtain the marrow cells. To ensure consistency across treatment groups, the same number and type of long bone (2 femurs, 1 tibia, and 2 humeri) were flushed and combined consistently between all animals. The bone marrow samples were then resuspended in basal minimum essential medium (␣-MEM; Sigma) containing 10% FBS (Invitrogen, Carlsbad, CA), 50 g/ml penicillin-streptomycin (Pen-Strep; Invitrogen, Carlsbad, CA), 15 mM HEPES (Sigma), and 130 M L-ascorbate (Sigma), as described (12) .
Histomorphometric analysis. Histomorphometric analysis of the growth plate and metaphysis bone was conducted to examine potential treatment effects on bone formation or bone volume. Paraffin sections were dewaxed and stained with 0.3% alcian blue in 3% acetic acid (pH 2.5), followed by routine haematoxylin and eosin (H & E) staining. Stained sections were used for morphometric measurements of growth plate total heights, heights of primary spongiosa, and bone volume of primary and secondary spongiosa metaphyseal bone using image analysis software AnalySIS (Olympus). Briefly, the entire height of the growth plate along an axis oriented 90°to the transverse of the growth plate and parallel to the longitudinal axis of the tibial bone was measured (12, 48, 49, 51, 52) . Similarly, the average primary spongiosa zonal height at the metaphysis was also obtained using the same software (12, 48, 49, 51, 52) . At both primary (0.1 mm above the primary-secondary transitional line) and secondary spongiosa (1 mm below the transitional line), total areas were measured and all trabecular cores traced, and the data were used to work out the ratio of bone volume to total tissue volume (BV/TV%), as described (12, 48, 49, 51, 52) .
Osteoblast and osteoclast density measurements in metaphyseal bone. Densities of osteoclasts and osteoblasts on trabecular bone surface were measured as a means to examine treatment effects on bone cell populations in the bone. Staining for tartrate-resistant acid phosphatase (TRAP; a marker of osteoclast function) was performed by incubating sections for 40 min at 37°C in acetate buffer with naphtal AS-BI phosphate (Sigma) and a solution of pararosanilline and sodium nitrate, as described (19) . Osteoclasts at both primary and secondary spongiosa (TRAP-positive cells containing Ն3 nuclei) along the trabecular surface were counted and expressed as osteoclasts/mm 2 trabecular bone area at metaphysis. Mononuclear cells that form a closely packed sheet along the trabecular surface were counted under the microscope and expressed as total number of osteoblasts/mm 2 trabecular bone area within primary spongiosa and secondary spongiosa.
Ex vivo osteoclast formation assay and TRAP staining. Treatment effects on osteoclastogenesis were analyzed using an ex vivo osteoclast formation assay (12) . Bone marrow cells obtained from the rats were cultured in ␣-MEM (Sigma) supplemented with 10% FBS (Invitrogen), 50 g/ml Pen-Strep (Invitrogen), 15 mM HEPES (Sigma), and 10 ng/ml M-CSF (Peprotech, Rocky Hill, NJ). Upon culturing overnight, nonadherent hematopoietic cells were collected and centrifuged. Cells were plated in 96-well plates at a density of 3 ϫ 10 5 cells/well in triplicate and cultured in medium containing ␣-MEM with 10% FBS, 50 g/ml Pen-Strep, 15 mM HEPES, 3 ng/ml M-CSF, and 5 ng/ml RANKL (Peprotech). Culture was maintained for 8 days, with medium change every 3 days. On day 8, the culture was fixed and processed for TRAP staining. Data are expressed as TRAP ϩ osteoclasts/mm 2 culture area.
RNA isolation and quantitative RT-PCR analysis of gene expression.
As a means to assess treatment effects on inflammatory condition and osteoclastogenesis potential in the bone, real-time RT-PCR gene analysis was conducted with RNA isolated from metaphysis samples for the following proinflammatory cytokines and osteoclast associated genes: IL-1, IL-6, TNF␣, RANKL, OPG, receptor activator of NF-B (RANK), and osteoclast-associated receptor (OSCAR). Since osteoclast density at the metaphysis bone was higher on day 4 based on histological analysis, gene expression analysis was focused only on this particular time point. Frozen metaphyseal bone on day 4 was crushed to powder in liquid nitrogen using a mortar and pestle and was extracted with Tri-reagent (Sigma) for RNA isolation. Quality and concentration of RNA were assessed using Nanodrop UV reader at 260 nm, and cDNA was generated using a High Capacity RNA to cDNA kit (Applied Biosystems). Apart from IL-1 and TNF␣ primers, which were designed previously (54), sequences for primers of genes of interest (Table 3) were designed using rat DNA sequences and NCBI Primer Blast software, whereby forward and reverse primers were designed in different exons, 80 -150 bp in length, GC content of 50 -60%, and melting temperature at 58 -62°C. Primers were ordered from Geneworks (Australia). Primer optimization and amplification efficiency tests were performed across a known concentration of cDNA template dilution series. Threshold cycle (C T) values vs. the template concentration were plotted to obtain a straight line and ensured that the slope was close to Ϫ3.33, with a r 2 value ϭ 0.98 or higher, and the efficiency of the reaction was Ն90% and Ͻ105%. SYBR Green PCR assays for each target molecule and internal reference cyclophilin A were then performed in parallel in Table 3 .
Primer sequences used for real-time RT-PCR analysis

Gene
Forward Primer (5=-3=) Reverse Primer (5=-3=)
RANK, receptor activator of nuclear factor-B; RANKL, receptor activator of nuclear factor-B ligand; OPG, osteoprotegerin; OSCAR, osteoclast-associated receptor; CYC-A, cyclophilin A. triplicate on these cDNA samples, and the average CT value of the triple reactions was later obtained for calculation. Analysis of gene expression was done by using the 2 Ϫ⌬⌬CT method and presented as fold change in relation to the normal control (26) .
Statistics. Statistical analysis was conducted using IBM SPSS Statistics 19 (Chicago, IL). Data in Figs. 1 and 2 were analyzed using 2-way ANOVA with a Tukey's post hoc test to compare the differences among groups within the same day and across all days to study the progression of the treatment across the duration of the trial (from days 3 to 5 post 5-FU). Within each day, labeled means without a common superscripted letter differ (P Ͻ 0.05). RT-PCR data in Fig. 3 were analyzed using one-way ANOVA with a Tukey's post hoc test (P Ͻ 0.05 significance). Data in the figures are presented as means Ϯ SE.
RESULTS
Treatment effects on the metaphysis structure. Growth plate total thickness was not affected by any of the treatment groups at any time points (P ϭ 0.15; data not shown). H 2 O ϩ 5-FU had reduced the primary spongiosa heights significantly compared with H 2 O ϩ Sal on days 3 (P ϭ 0.015) and 5 (P Ͻ 0.0001) post-5-FU; however, no effects were observed on day 4 (P ϭ 0.27). EO ϩ 5-FU-treated rats were shown to have maintained the primary spongiosa heights on those days (P Ͻ 0.0001 on day 3 and P ϭ 0.001 on day 5) compared with rats just treated with H 2 O ϩ 5-FU (Fig. 1, A-D) . On day 4, the primary spongiosa height was not affected. BV/TV% at the primary spongiosa was unaffected by H 2 O ϩ 5-FU on all days compared with H 2 O ϩ Sal (P ϭ 1.00 on days 3 and 4, P ϭ 0.97 on day 5); however, EO ϩ 5-FU had a significantly higher bone volume compared with H 2 O ϩ 5-FU (P ϭ 0.031) only on day 3 and not on other days (P ϭ 0.58 on day 4 and P ϭ 0.10 on day 5; Fig. 1, A, B, C, and E) . On the other hand, the secondary spongiosa bone volume (BV/TV%) was reduced significantly by H 2 O ϩ 5-FU only on days 3 and 4 (P Ͻ 0.0001), compared with H 2 O ϩ Sal, but not on day 5 (P ϭ 0.22). Similarly, EO ϩ 5-FU preserved the bone volume compared with the H 2 O ϩ 5-FU group on day 3 (P ϭ 0.004) and to a greater extent on day 4 (P Ͻ 0.0001) (Fig. 1F) . However, by day 5, none of the treatment groups affected the bone volume. Administration of EO to the Sal group had a significantly higher bone volume than the H 2 O ϩ 5-FU group on day 3 (P ϭ 0.044) and not on days 4 and 5. Although H 2 O ϩ 5-FU did not cause a significant reduction in osteoblast density at the metaphysis compared with H 2 O ϩ Sal at all time points (P ϭ 0.99 on day 3, P ϭ 1.00 on days 4 and 5), EO ϩ 5-FU elevated the osteoblast density significantly compared with the H 2 O ϩ 5-FU group, particularly on day 3 (P ϭ 0.037) but not on other days (P ϭ 1.00 on day 4 and P ϭ 0.25 on day 5). The EO ϩ Sal group also showed a significant increase (P ϭ 0.041) in osteoblast density against the H 2 O ϩ 5-FU group on day 3 only (Fig. 1G) .
Treatment effects on osteoclast density at the metaphysis and ex vivo osteoclastogenesis.
A higher osteoclast density (P ϭ 0.048) on day 4 at the metaphysis (in both the primary and secondary spongiosa regions) was observed in the H 2 O ϩ 5-FU group compared with H 2 O ϩ Sal. However, H 2 O ϩ 5-FU treatment did not cause significant changes in osteoclast density on days 3 (P ϭ 1.00) and 5 (P ϭ 0.12) (Fig. 2A) . EO ϩ 5-FU had a trend for a reduced osteoclast density compared with H 2 O ϩ 5-FU (P ϭ 0.13). On day 5 only, the EO ϩ Sal group had a significantly lower osteoclast density in relation to the H 2 O ϩ 5-FU group (P ϭ 0.028). On days 3 and 4, although there was a slight increase in osteoclasts formed ex vivo from isolated bone marrow cells in the H 2 O ϩ 5-FU group compared with H 2 O ϩ Sal, none of the treatments made a significant difference (P Ͼ 0.05; Fig. 2B ).
Effects on expression of inflammatory cytokines and osteoclastogenesis-related genes.
On day 4 post-5-FU (a time point found to have a higher osteoclast density in the 5-FU-treated rats), mRNA expression levels of the proinflamamtory cytokines IL-1 and IL-6 did not change across the treatment groups (Fig. 3, A and  B) . Expression level of TNF␣ was approximately fivefold higher in the H 2 O ϩ 5-FU group (P ϭ 0.026), which was significantly higher than that of the H 2 O ϩ Sal group. EO ϩ 5-FU (P ϭ 0.042) suppressed 5-FU-induced TNF␣ upregulation significantly (Fig.  3C) . None of the treatment groups made a significant change in the expression levels of RANKL, OPG (data not shown), or the RANKL/OPG ratio (P Ͼ 0.05; Fig. 3D ). RANK was upregulated significantly in the H 2 O ϩ 5-FU group (P ϭ 0.021) relative to H 2 O ϩ Sal, and EO ϩ 5-FU had suppressed the RANK upregulation significantly compared with the H 2 O ϩ 5-FU group (P ϭ 0.047) (Fig. 3E) . Consistent with the higher osteoclast density in the H 2 O ϩ 5-FU group on day 4, OSCAR expression was significantly higher in H 2 O ϩ 5-FU treated rats (15-fold higher) (P ϭ 0.009) compared with the H 2 O ϩ Sal. OSCAR expression was significantly attenuated in the EO ϩ 5-FU and EO ϩ Sal groups (P ϭ 0.030 and P ϭ 0.010, respectively) compared with H 2 O ϩ 5-FU (Fig. 3F) .
The above results have also been summarized and depicted in Table 4 .
DISCUSSION
Chemotherapy with 5-FU, a commonly used antimetabolite drug for breast and colon cancers, has been shown to cause bone pain, osteoporosis, and fracture (7, 28) . Currently, mechanisms for 5-FU-induced bone defects are unclear, and there has been a lack of effective supplementary treatments to protect bone during cancer chemotherapy. The purpose of our current investigation was to elucidate whether supplementation with EO can prevent or reduce the damage caused by 5-FU chemotherapy and/or improve or hasten the recovery in the bone. Using a rat acute 5-FU chemotherapy model, this current study examined effects of 5-FU chemotherapy on primary spongiosa height, bone volume, bone cells, and the local bone inflammatory condition and addressed the potential protective effects of supplementary treatment with emu oil, which is known to possess an anti-inflammatory property.
Growth plate and the primary spongiosa of the metaphysis are part of the "active growth unit." In this study, consistent with a previous finding (48) , height of primary spongiosa was affected only on days 3 and 5 and not on day 4. However, the obvious reduction in height was also noted between days 5 and 10 in that previous study. Height retardation as a consequence of 5-FU has been reflected on the primary spongiosa since this is where the resorption of growth plate cartilage template and formation of trabecular bone occur during endochondral ossification (52) . The present study also observed a decreased bone volume at the secondary spongiosa and a slight suppression of osteoblasts but increased osteoclast formation and density, especially on day 4 post-5-FU. In addition, the present study showed that 5-FU chemotherapy induced an inflammatory condition in bone by upregulating proinflammatory cytokines and osteoclast regulatory factors. These suggest that 5-FU treatment increases osteoclast presence. Therefore, the higher osteoclast density and bone resorption (but no significant difference on the osteoblast density) could have contributed to the bigger bone loss seen in the secondary spongiosa on day 4, a region where bone remodeling is actively occurring.
The underlying mechanism for 5-FU-induced increased osteoclast formation and density remains to be investigated. Since formation, number, and activity of osteoclasts are regulated by a number of inflammatory molecules or modulators (21) , expression of the key osteoclastogenic molecules or modulators at the metaphyseal bone from the treated rats was analyzed in the current study. Our data showed that, consistent with the increased osteoclast density on day 4, there were a significant increase in TNF␣, RANK, and OSCAR mRNA expressions in bone. Previously, TNF␣ has been shown to be a potent stimulator of bone resorption and can promote osteoclastogenesis directly or via the RANKL induction pathway (22, 35) . Consistent with the increased osteoclastogenesis and higher osteoclast density in H 2 O ϩ 5-FU-treated rats observed on day 4, RANK and OSCAR, which are expressed specifically on osteoclast lineage cells and responsible for osteoclast differentiation and activity (30) , were upregulated significantly in bone. These findings suggest that 5-FU chemotherapy might be able to create an inflammatory microenvironment in the bone, causing increased levels of proinflammatory cytokines that may be responsible for stimulating osteoclastic bone resorption. Previous studies using rat models have demonstrated that MTX, another chemotherapeutic agent, decreases trabecular bone volume and causes bone loss that is associated with a low osteoblast number, higher osteoclast density on the bone surface, and increased osteoclast progenitor cell number in the bone marrow (12, 50) . Similarly, the increase in osteoclast numbers and activity has also been shown to be associated with an increase in proinflammatory cytokines in circulation in patients undergoing chemotherapy (11, 37).
Many chemotherapeutic agents also induce the production of free radicals, which may be another mechanism for chemotherapy drugs to exert toxic effects on normal cells (10, 41) . Some clinical studies have documented that oxidative stress might be playing a role in the pathogenesis of bone loss, and the reactive oxygen species formed are potent inducers of proinflammatory cytokines (3, 29) . Osteoclasts have been shown to be activated by reactive oxygen species to enhance bone resorption (13, 18) . A study has shown that 5-FU induces oxidative stress in bone marrow (31) . However, the precise role of oxidative stress caused by 5-FU still remains to be studied, and further studies are required to investigate whether the oxidative stress enhances osteoclast formation via inducing inflammatory cytokines in the 5-FU chemotherapy setting.
In the current study, an inflammatory condition was identified in bone after 5-FU chemotherapy; thus this study also sought to examine whether the nutraceutical EO (which is known to possess a potential anti-inflammatory property) would have some protective effects on bone during 5-FU chemotherapy. Here, EO supplementation (EO ϩ 5-FU) was shown to significantly preserve the height of the primary spongiosa (days 3 and 5) and bone volume at the secondary spongiosa, which were reduced by H 2 O ϩ 5-FU (days 3 and 4) . EO supplementation significantly preserved the osteoblast density especially on day 3 after H 2 O ϩ 5-FU administration and prevented 5-FU-induced higher osteoclast density in the metaphysis. Although the mechanisms for EO-induced preservation of osteoblast density remain to be studied, it is known that a constant supply of osteoblasts is required for normal bone formation and homeostasis, and any significant reduction in osteoblast numbers and activity can result in reduced bone formation and lead to osteoporosis (8, 49, 51) . Although the underlying mechanisms for EO's antiosteoclastic effects remain to be defined, consistent with its effects in suppressing 5-FU-induced osteoclastogenesis, our gene expression studies suggest that EO supplementation can suppress the induction of proinflammatory cytokines, particularly TNF␣ and osteoclast receptors RANK and OSCAR, which were upregulated by (53) . A study conducted in CD-1 mice has shown that EO's anti-inflammatory property was associated with suppression of the induced expression of proinflammatory cytokines IL-1 and TNF␣ (53).
Our current study suggests a potential role for EO in the treatment of chemotherapy-induced inflammatory bone loss. Consistently, a previous study has shown that EO supplementation was able to decrease 5-FU chemotherapy-associated inflammation in an intestinal mucosal damage (mucositis) model (24) . A number of hypotheses relate to the potential mechanism by which EO exerts its anti-inflammatory effects; 18:3 (n-3) polyunsaturated fatty acids have been shown to suppress TNF␣ expression levels in humans (23) and to inhibit RANK expression and osteoclast formation (39, 44) . It has been suggested that the linolenic acid and oleic acid present in EO may be involved in its anti-inflammatory action (53) . However, it has been proposed that the anti-inflammatory properties of EO may not be fully explained by the fatty acid profile and that its other components, such as tocopherols, carotenoids, and flavones, may exert additional anti-inflammatory (42) and antioxidant (45) effects. A recent study has suggested that the radical scavenging properties of EO were most likely due to the minor constituents in the nontriglyceride fraction of the oil (2), which, in combination with the fatty acid components, offered greater protection against oxidation. These antioxidants may have impacted on levels of damaging reactive oxygen species that are generated during chemotherapy. However, since the content of 18:3 (n-3) fatty acids is not particularly high in EO (4), it is speculated that probably the nontriglyceride components of EO might be contributing to its antiosteoclastic effect after 5-FU chemotherapy observed in the current study. The promising anti-inflammatory effects displayed by EO in previous studies (24, 53) and the positive effects of EO in preventing osteoclast formation and bone loss after 5-FU chemotherapy suggest its therapeutic potential in preventing chemotherapy-induced inflammatory condition and bone loss.
In the current study, a set amount of EO (unadjusted by body weight) had been gavaged to the rats (1.0 ml/day). However, the differences in daily body weight change between H 2 O ϩ Sal and H 2 O ϩ 5-FU-treated rats were found to be relatively minor, with the maximal difference being only 13 g in average body weight between controls (111 g) and 5-FU rats (98 g) during the trial (which was evident on day 4 after 5-FU); this small body weight difference would have equated to only a 0.12-ml difference between minimum and maximum gavage volumes. Considering that the gavaged dose (1.0 ml/day) had been a relatively large dose for rats, it is believed that such a minor difference in body weight would not have impacted significantly on the outcomes of any of the end point analyses. However, further studies are required to determine the minimal effective dose of EO in preventing 5-FU chemotherapy-induced bone loss. More studies are required to also investigate the active components of EO responsible and the action mechanisms for the anti-inflammatory and antiosteoclastic properties of EO.
In summary, the current study demonstrated that acute 5-FU chemotherapy induced an inflammatory condition in bone, increased osteoclast formation, and caused bone loss as shown by reduced primary spongiosa height and decreased secondary spongiosa bone volume. The present study has also provided some evidence that EO has an antiosteoclastic and osteotrophic property and has shown encouraging data suggesting that EO might be useful in suppressing inflammatory condition and osteoclast formation and preventing bone loss induced during 5-FU chemotherapy. Further studies are required with models for a longer course of chemotherapy, with more time points and an earlier and extended observation period, and possibly in a tumour-bearing model to obtain a more comprehensive profile for both cell types (osteoblasts and osteoclasts) and a better understanding of the mechanisms leading to bone loss and the effects of EO in protecting bone during chemotherapy. In our previous study (48) , we observed that, although there were no obvious structural changes of metaphyseal trabecular bone on days 1 and 2 post-5-FU treatment, there were a significant induction of osteoblast apoptosis and a suppression of osteoblast proliferation on these earlier time points. Since the osteoblast number and activity affect osteoclast formation (via production of osteoclastogenesis regulatory cytokines), it is possible that changes in osteoblasts in the earlier time points (48) might have played a role in causing the osteoclast formation and greater bone loss at a later time (day 4; observed in current study). Further studies (e.g., with more time points and extended treatment periods) are required to fully understand the time course of cellular and histological responses, cellular cross-talks, and molecular mechanisms underlying 5-FU-induced bone loss and EO-protective effects.
